Provided by Tiger Trade Technology Pte. Ltd.

Natera

336.71
+8.992.74%
Post-market: 339.372.66+0.79%18:08 EDT
Volume:1.73M
Turnover:575.32M
Market Cap:48.22B
PE:-245.26
High:337.12
Open:330.31
Low:325.98
Close:327.72
52wk High:337.12
52wk Low:157.43
Shares:143.22M
Float Shares:139.00M
Volume Ratio:1.22
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3729
EPS(LYR):-1.5269
ROE:-12.54%
ROA:-8.08%
PB:26.47
PE(LYR):-220.53

Loading ...

GUIDANCE: (NTRA) Natera Expects Full Year 2026 Revenue Range $2.85B - $2.91B, vs. FactSet Est of $2.80B

MT Newswires Live
·
Aug 07

Earnings Flash (NTRA) Natera Posts Q2 Loss $0.47, vs. FactSet Est of $0.49 Loss

MT Newswires Live
·
Aug 07

Movement Alert|Natera Rises 8.15% in After-Hours Trading, Positive Market Reaction Following Quarterly Earnings Release

Market Focus
·
Aug 07

Natera Q2 EPS USD -0.47

Reuters
·
Aug 07

Natera’s SCORE-NHL Study Builds Long-Term Value in Lymphoma Monitoring

TIPRANKS
·
Aug 07

Natera CFO Michael Burkes Brophy Disposes of 795 Common Shares Worth $215,449.79

Reuters
·
Aug 06

Natera Seeks Japan PMDA Approval for Signatera Test in Muscle-Invasive Bladder Cancer

Reuters
·
Aug 05

Movement Alert|Natera Rises 5.08% in Regular Trading, Strong Earnings Preview and Signatera Milestones Drive Momentum

Market Focus
·
Jul 31

Natera Schedules Second-quarter Results Conference Call

Reuters
·
Jul 30

Press Release: Natera to Report Its Second Quarter Results on August 6, 2026

Dow Jones
·
Jul 30

Natera CFO Michael Burkes Brophy Disposes of USD 1.29 Million in Common Shares

Reuters
·
Jul 30

Natera’s New ctDNA-Guided Immunotherapy Trial Could Redefine Cancer Treatment Cycles

TIPRANKS
·
Jul 25

Natera (NTRA) Gets a Buy from BTIG

TIPRANKS
·
Jul 23

Bernstein Sticks to Their Buy Rating for Natera (NTRA)

TIPRANKS
·
Jul 23

J.P. Morgan Remains a Buy on Natera (NTRA)

TIPRANKS
·
Jul 22

Natera reports results from multicenter study in MCC

TIPRANKS
·
Jul 22

Natera Notifies Availability of Press Release on Signatera Merkel Cell Carcinoma Study in JAMA Dermatology

Reuters
·
Jul 22

Natera (NTRA) On Prospera Coverage Expansion And Revenue Strength Looks Fully Valued

Simply Wall St.
·
Jul 18

Natera Co-founder, Director Sheena Jonathan Disposes of 1,500 Common Shares Worth $410,322.91

Reuters
·
Jul 18

Natera Says Finalized Moldx Coverage Expands Prospera Surveillance Testing for Kidney, Heart, Lung Transplants

Reuters
·
Jul 17